Standard of care chemoradiation for stage III non-small cell lung cancer is superior to two tested alternatives

by NRG OncologyCredit: CC0 Public DomainLung cancer is the leading cause of cancer death in the United States and approximately 75-80 percent of all cases are non-small cell lung cancer (NSCLC). Of th

Updated on: December 22,2023

Standard of care chemoradiation for stage III non-small cell lung cancer is superior to two tested alternatives

by NRG OncologyCredit: CC0 Public DomainLung cancer is the leading cause of cancer death in the United States and approximately 75-80 percent of all cases are non-small cell lung cancer (NSCLC). Of th

Updated on:December 22,2023

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on: October 24,2023

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on:October 24,2023

New tool gives deeper understanding of glioblastoma

byCornell UniversityGlioblastoma (histology slide). Credit: Wikipedia/CC BY-SA 3.0Researchers in the lab of Charles Danko at the Baker Institute for Animal Health have developed a new tool to st

Updated on: December 18,2023

New tool gives deeper understanding of glioblastoma

byCornell UniversityGlioblastoma (histology slide). Credit: Wikipedia/CC BY-SA 3.0Researchers in the lab of Charles Danko at the Baker Institute for Animal Health have developed a new tool to st

Updated on:December 18,2023

Weekly Update of Drug News-23/12/2024

Weekly update of drug news.

Updated on: December 27,2024

Weekly Update of Drug News-23/12/2024

Weekly update of drug news.

Updated on:December 27,2024

Carbon oxide gas boosts photothermal therapy under mild temperature

by ZHANG Nannan,Chinese Academy of SciencesSchematic illustration of (A) synthesis route of mPEG(CO) and (B) the nanobomb consist of mPEG(CO) and PBPTV. (C) Schematic illustration of low-tempera

Updated on: December 22,2023

Carbon oxide gas boosts photothermal therapy under mild temperature

by ZHANG Nannan,Chinese Academy of SciencesSchematic illustration of (A) synthesis route of mPEG(CO) and (B) the nanobomb consist of mPEG(CO) and PBPTV. (C) Schematic illustration of low-tempera

Updated on:December 22,2023

Predicting lymphoma patients' treatment outcomes

byCedars-Sinai Medical CenterDistinct spatially resolved TME features according to relapse status. (A) Proportion for the indicated immune cell population by IMC-based cluster assignment. (B) Th

Updated on: December 26,2023

Predicting lymphoma patients' treatment outcomes

byCedars-Sinai Medical CenterDistinct spatially resolved TME features according to relapse status. (A) Proportion for the indicated immune cell population by IMC-based cluster assignment. (B) Th

Updated on:December 26,2023

Patient's own immune cells effective as living medicine for melanoma

byNetherlands Cancer InstitutePreparing tumor-infiltrating lymphocyte therapy for melanoma patients in the lab. Credit: NKIA patient's own immune cells, multiplied into an army of billions o

Updated on: December 19,2023

Patient's own immune cells effective as living medicine for melanoma

byNetherlands Cancer InstitutePreparing tumor-infiltrating lymphocyte therapy for melanoma patients in the lab. Credit: NKIA patient's own immune cells, multiplied into an army of billions o

Updated on:December 19,2023

Vemurafenib Induces Deep, Durable Remissions in Heavily Pretreated Hairy Cell Leukemia

October 25, 2019Kristi RosaAgnieszka Janus, MD, PhD, shares perspective on three cases of patients with HCL who were given vemurafenib after having progressed on multiple lines of treatment.Agnieszka

Updated on: October 24,2023

Vemurafenib Induces Deep, Durable Remissions in Heavily Pretreated Hairy Cell Leukemia

October 25, 2019Kristi RosaAgnieszka Janus, MD, PhD, shares perspective on three cases of patients with HCL who were given vemurafenib after having progressed on multiple lines of treatment.Agnieszka

Updated on:October 24,2023

“The power of science”: HPV vaccine proven to dramatically reduce cervical cancer

byLilly Matson| Analysis3 November 2021Share this articleAlmost all cervical cancers are caused by the human papilloma virus (HPV), depicted above.After decades of research,the UK im

Updated on: December 19,2023

“The power of science”: HPV vaccine proven to dramatically reduce cervical cancer

byLilly Matson| Analysis3 November 2021Share this articleAlmost all cervical cancers are caused by the human papilloma virus (HPV), depicted above.After decades of research,the UK im

Updated on:December 19,2023

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

New data released demonstrates that the addition of Zometa (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than che

Updated on: October 27,2023

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

New data released demonstrates that the addition of Zometa (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than che

Updated on:October 27,2023

Engineering the immune system to tackle glioblastoma

by Sally Sapega,University of PennsylvaniaCredit: University of PennsylvaniaEach year, roughly 15,000 Americans are diagnosed with Glioblastoma Multiforme (GBM), the most common malignant primar

Updated on: December 22,2023

Engineering the immune system to tackle glioblastoma

by Sally Sapega,University of PennsylvaniaCredit: University of PennsylvaniaEach year, roughly 15,000 Americans are diagnosed with Glioblastoma Multiforme (GBM), the most common malignant primar

Updated on:December 22,2023

Scientists map genetic evolution of chronic lymphocytic leukemia to Richter's syndrome

byDana-Farber Cancer InstituteCredit: Pixabay/CC0 Public DomainEvery year, up to 1% of patients with chronic lymphocytic leukemia (CLL), a slow-growing blood cancer, have their disease transform

Updated on: December 27,2023

Scientists map genetic evolution of chronic lymphocytic leukemia to Richter's syndrome

byDana-Farber Cancer InstituteCredit: Pixabay/CC0 Public DomainEvery year, up to 1% of patients with chronic lymphocytic leukemia (CLL), a slow-growing blood cancer, have their disease transform

Updated on:December 27,2023